Cardiac Failure Review最新文献

筛选
英文 中文
Obesity Phenotypes Causally Affect Cardiac MRI Structure and Induced Non-ischaemic Cardiomyopathy. 肥胖表型影响心脏MRI结构和诱导非缺血性心肌病。
IF 4.2
Cardiac Failure Review Pub Date : 2025-05-09 eCollection Date: 2025-01-01 DOI: 10.15420/cfr.2024.26
Long Peng, Tao Zeng, Enxi Quan, Shufang Pan, Bin Li, Zheqi Wen, Zhaojun Xiong, Yunyue Zhao
{"title":"Obesity Phenotypes Causally Affect Cardiac MRI Structure and Induced Non-ischaemic Cardiomyopathy.","authors":"Long Peng, Tao Zeng, Enxi Quan, Shufang Pan, Bin Li, Zheqi Wen, Zhaojun Xiong, Yunyue Zhao","doi":"10.15420/cfr.2024.26","DOIUrl":"10.15420/cfr.2024.26","url":null,"abstract":"<p><strong>Background: </strong>The growing obesity epidemic highlights the need to understand how various obesity phenotypes affect myocardial structure and increase non-ischaemic cardiomyopathy (NICM) incidence. The aim of this study was to investigate the causal effect of eight obesity-related traits on NICM and 16 cardiac MRI parameters. Potential mediators between obesity and NICM were also investigated.</p><p><strong>Methods: </strong>Two-sample Mendelian randomisation was used to explore the causal relationship between eight obesity-related traits and NICM and assess their impact on cardiac MRI indicators. The study also used validation dataset analysis and multivariable Mendelian randomisation to ensure robustness, and mediation Mendelian randomisation analysis to identify metabolic markers as potential mediators.</p><p><strong>Results: </strong>All eight obesity-related traits demonstrated a causal relationship with NICM, with the relationship between BMI and NICM persisting after adjustment for LDL cholesterol, urate level and hypertension (HTN). These traits also influenced arterial and cardiac structure and function, especially with regard to left ventricular mass. HTN was identified as a significant mediator, with a mediation effect ratio of 31%.</p><p><strong>Conclusion: </strong>There is a robust causal association between obesity and NICM, and with abnormalities in myocardial structure and function. HTN emerges as a pivotal mediator in the obesity-NICM pathway, underscoring the critical role of managing obesity and HTN in preventing NICM progression.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"11 ","pages":"e10"},"PeriodicalIF":4.2,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12090072/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144112023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cardiac Dysfunction and Subclinical Atherosclerosis in Post-COVID-19 Patients. covid -19后患者心功能障碍与亚临床动脉粥样硬化
IF 4.2
Cardiac Failure Review Pub Date : 2025-04-15 eCollection Date: 2025-01-01 DOI: 10.15420/cfr.2024.21
Angela Cozma, Violeta Briciu, Adela Viviana Sitar-Tăut, Daniel Leucuţa, Nicolae-Dan Sporiş, Andrada-Luciana Lazar, Toma-Vlad Mălinescu, Andreea-Maria Ganea, Călin Vasile Vlad, Mihaela Lupşe, Adriana Fodor, Andreea Terec, Ramona Suharoschi, Madalina Indre, Olga Hilda Orăşan
{"title":"Cardiac Dysfunction and Subclinical Atherosclerosis in Post-COVID-19 Patients.","authors":"Angela Cozma, Violeta Briciu, Adela Viviana Sitar-Tăut, Daniel Leucuţa, Nicolae-Dan Sporiş, Andrada-Luciana Lazar, Toma-Vlad Mălinescu, Andreea-Maria Ganea, Călin Vasile Vlad, Mihaela Lupşe, Adriana Fodor, Andreea Terec, Ramona Suharoschi, Madalina Indre, Olga Hilda Orăşan","doi":"10.15420/cfr.2024.21","DOIUrl":"https://doi.org/10.15420/cfr.2024.21","url":null,"abstract":"<p><strong>Background: </strong>The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is still a burden for healthcare systems worldwide. Now, the focus is not only on acute infections, but also on the long-term effects of COVID-19. The present study aimed to evaluate the impact of SARS-CoV-2 infection on the cardiovascular system, and determine the evolution of these changes over 6 months in patients with mild and moderate COVID-19.</p><p><strong>Methods: </strong>The prospective observational study included 103 patients with mild and moderate COVID-19. The patients underwent an echocardiography and a measurement of the arterial stiffness parameters at baseline and 6 months from the initial assessment.</p><p><strong>Results: </strong>The diastolic dysfunction (the left atrium volume) was statistically significant at baseline and at the 6-month follow-up in men with moderate COVID-19. The ejection fraction presented significant differences globally in mild versus moderate COVID-19 (p=0.043) that disappeared at 6-month follow-up. Global longitudinal strain alterations were also found in both mild and moderate COVID-19 cases. Regarding the aortic pulse wave velocity, the SARS-CoV-2 infection did not influence the arterial stiffness. Ventricular arterial coupling was significantly altered in moderate COVID-19 at the 6-month evaluation (p=0.0218). Male patients presented a lower tricuspid annular plane systolic excursion at baseline. Right ventricular systolic dysfunction was more frequent among men. Systolic pulmonary arterial pressure increased significantly only in men with moderate disease. Additionally, statistically significant changes at baseline and at 6 months were found regarding the intima-media thickness.</p><p><strong>Conclusion: </strong>This study shows the cardiovascular long-term sequelae associated with COVID-19 in mild and moderate cases, and emphasises the appropriate investigations for their diagnosis and follow-up.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"11 ","pages":"e09"},"PeriodicalIF":4.2,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12042291/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144037479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Arrhythmias and Sudden Death: What is New in Hypertrophic Cardiomyopathy? 心律失常和猝死:肥厚性心肌病有什么新发现?
IF 4.2
Cardiac Failure Review Pub Date : 2025-04-01 eCollection Date: 2025-01-01 DOI: 10.15420/cfr.2024.38
Deepthi Rajan, Christopher Ryan Zörner, Morten Lock Hansen, Jacob Tfelt-Hansen
{"title":"Arrhythmias and Sudden Death: What is New in Hypertrophic Cardiomyopathy?","authors":"Deepthi Rajan, Christopher Ryan Zörner, Morten Lock Hansen, Jacob Tfelt-Hansen","doi":"10.15420/cfr.2024.38","DOIUrl":"https://doi.org/10.15420/cfr.2024.38","url":null,"abstract":"<p><p>Hypertrophic cardiomyopathy (HCM) is a complex genetic disorder that has garnered significant attention because of its diverse manifestations, including arrhythmias and heightened risk of sudden cardiac death. Advances in precision diagnostics, such as genetic testing and cardiac imaging with late gadolinium enhancement, have refined HCM diagnosis, enabling targeted therapeutic and risk stratification approaches. AF, prevalent in HCM, exacerbates symptoms and stroke risk, while ventricular arrhythmias pose a direct threat to survival. Catheter ablation offers symptom relief in AF patients with HCM, yet recurrence remains high because of unique myocardial changes, highlighting the need for refined patient selection and long-term monitoring. The risk of sudden cardiac death in HCM, particularly in younger individuals, underscores the importance of precise risk stratification tools such as the European Society of Cardiology HCM Risk-SCD model. The expanding role of ICDs and emerging pharmacological agents, including myosin inhibitors, marks a shift toward more individualised management of HCM. This review integrates recent developments in arrhythmia management, targeted therapies and risk assessment, offering a comprehensive perspective on HCM tailored to improve clinical outcomes through a precision-medicine lens.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"11 ","pages":"e08"},"PeriodicalIF":4.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12001045/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144027368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Addressing 'Residual Congestion' to Improve Prognosis After Acute Heart Failure Decompensation. 解决“残余充血”改善急性心力衰竭失代偿后的预后。
IF 4.2
Cardiac Failure Review Pub Date : 2025-03-24 eCollection Date: 2025-01-01 DOI: 10.15420/cfr.2024.24
Aleksandra Gąsecka, Aleksander Siniarski
{"title":"Addressing 'Residual Congestion' to Improve Prognosis After Acute Heart Failure Decompensation.","authors":"Aleksandra Gąsecka, Aleksander Siniarski","doi":"10.15420/cfr.2024.24","DOIUrl":"10.15420/cfr.2024.24","url":null,"abstract":"<p><p>Congestion is the hallmark and the main therapeutic target in patients with decompensated heart failure (HF). Residual clinical congestion is defined as a high left ventricular diastolic pressure associated with signs and symptoms of HF, such as dyspnoea, rales and oedema, persisting despite guideline-directed medical treatment. Residual congestion in the predischarge and early post-discharge phase is the major risk factor for HF readmission and mortality. Therefore, prompt recognition of congestion and rapid optimisation of medical and device therapy are crucial to induce remission in this malignant process. In this paper we discuss the definitions, prevalence and prognosis of HF decompensation; the significance of assessing residual congestion in HF patients; the results of observational and randomised clinical trials to detect and treat residual congestion; and the current guidelines to prevent recurrent HF decompensation in the context of residual congestion. Strategies to detect and address residual congestion are crucial to stopping readmissions after an acute HF hospitalisation and improving long-term prognosis.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"11 ","pages":"e06"},"PeriodicalIF":4.2,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11959577/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143765147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
History of Heart Failure Definition. 心力衰竭的定义。
IF 4.2
Cardiac Failure Review Pub Date : 2025-03-24 eCollection Date: 2025-01-01 DOI: 10.15420/cfr.2024.22
Raluca Ibănescu, Diana-Alexandra Mîțu, Iacob-Daniel Goje, Greta-Ionela Goje, Daniel-Florin Lighezan
{"title":"History of Heart Failure Definition.","authors":"Raluca Ibănescu, Diana-Alexandra Mîțu, Iacob-Daniel Goje, Greta-Ionela Goje, Daniel-Florin Lighezan","doi":"10.15420/cfr.2024.22","DOIUrl":"10.15420/cfr.2024.22","url":null,"abstract":"<p><p>The concept of heart failure (HF) has undergone significant transformation from ancient times to the present, evolving from rudimentary understandings to a complex clinical syndrome. Early descriptions by Egyptian, Greek and Roman physicians laid the groundwork for understanding cardiac dysfunction. The Renaissance period brought crucial insights with Harvey's discovery of blood circulation. In the 20th century, the Framingham Heart Study provided a pivotal shift, formally defining HF as a clinical syndrome with diagnostic criteria. Over the decades, definitions of HF have evolved, integrating advancements in pathophysiology, biomarkers and imaging techniques. Initially focused on symptomatic and clinical presentations, modern definitions emphasise underlying structural and functional cardiac abnormalities. This evolution reflects the growing complexity and precision of diagnosing and managing HF. A historical perspective underscores the progressive refinement in HF definitions, which enhances diagnostic precision and therapeutic strategies, ultimately improving patient outcomes. Understanding this evolution is crucial for appreciating contemporary HF management and anticipating future advances.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"11 ","pages":"e07"},"PeriodicalIF":4.2,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11959578/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143765054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Frailty and Heart Failure: Clinical Insights, Patient Outcomes and Future Directions. 虚弱和心力衰竭:临床观察,患者结果和未来方向。
IF 4.2
Cardiac Failure Review Pub Date : 2025-02-26 eCollection Date: 2025-01-01 DOI: 10.15420/cfr.2024.34
Karol Mirkowski, Ercole Vellone, Bernadetta Żółkowska, Maria Jędrzejczyk, Micha Czapla, Izabella Uchmanowicz, Bartosz Uchmanowicz
{"title":"Frailty and Heart Failure: Clinical Insights, Patient Outcomes and Future Directions.","authors":"Karol Mirkowski, Ercole Vellone, Bernadetta Żółkowska, Maria Jędrzejczyk, Micha Czapla, Izabella Uchmanowicz, Bartosz Uchmanowicz","doi":"10.15420/cfr.2024.34","DOIUrl":"10.15420/cfr.2024.34","url":null,"abstract":"<p><p>Frailty is common among heart failure (HF) patients and linked to increased risk of adverse outcomes. Contributing factors include inflammation, sarcopenia and neurohormonal issues which diminish physiological reserves and accelerate the decline of health. Managing frailty in HF requires a multidisciplinary approach to address physical, nutritional and pharmacological needs. Structured exercise and dietary support can improve physical function, while careful medication management, especially with polypharmacy, reduces frailty-related risks. Telemedicine and wearable tech facilitate continuous monitoring and timely intervention, especially for those in remote areas. Future research should develop standardised frailty assessment tools specific to HF, enhancing risk stratification and personalised care. Studies on underlying mechanisms, such as inflammation and mitochondrial dysfunction, could lead to new therapies. Addressing socioeconomic factors can also improve care equity. This review summarises the mechanisms, clinical characteristics and impact of frailty on HF, highlighting challenges in treatment and opportunities for improving patient outcomes.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"11 ","pages":"e05"},"PeriodicalIF":4.2,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11904417/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143625962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Associations of Obesity and Prognostic Nutritional Index on 1-Year Mortality in Patients with Acute Heart Failure. 肥胖和预后营养指数与急性心力衰竭患者1年死亡率的关系
IF 4.2
Cardiac Failure Review Pub Date : 2025-02-19 eCollection Date: 2025-01-01 DOI: 10.15420/cfr.2024.35
Mohammed El-Sheikh, Nora Olsen El Caidi, Aginsha Kandiah, Sandra Henriette Tonning, Ida Arentz Taraldsen, Frederik Dencker Wisborg, Ove Andersen, Jens Dahlgaard Hove, Johannes Grand
{"title":"Associations of Obesity and Prognostic Nutritional Index on 1-Year Mortality in Patients with Acute Heart Failure.","authors":"Mohammed El-Sheikh, Nora Olsen El Caidi, Aginsha Kandiah, Sandra Henriette Tonning, Ida Arentz Taraldsen, Frederik Dencker Wisborg, Ove Andersen, Jens Dahlgaard Hove, Johannes Grand","doi":"10.15420/cfr.2024.35","DOIUrl":"10.15420/cfr.2024.35","url":null,"abstract":"<p><strong>Background: </strong>Increased BMI is paradoxically associated with improved survival among patients with acute heart failure (AHF). However, the impact of different nutritional status on this obesity paradox on 1-year mortality is underreported. The prognostic nutritional index is a simple tool to assess nutrition status.</p><p><strong>Methods: </strong>From 10,027 emergency department admissions at the Amager and Hvidovre Hospital, Copenhagen University Hospital in Denmark, all patients with AHF were identified. Patients were categorised by BMI (normal: 18.5-24.9 kg/m<sup>2</sup>, overweight: 25-29.9 kg/m<sup>2</sup>, obese: ≥30 kg/m<sup>2</sup>) and nutritional status using the prognostic nutritional index (malnourished: <38, well-nourished: ≥38). Kaplan- Meier curves analysed cumulative survival, and Cox regression examined associations between BMI, nutritional status and outcomes, expressed as HR and 95% CI.</p><p><strong>Results: </strong>Among 383 AHF patients (median age 76 years), 41.3% were malnourished and 58.7% well nourished. In the well-nourished group, obesity was inversely associated with 1-year mortality (adjusted HR 0.48; 95% CI [0.24-0.95]; p=0.035). However, this correlation disappeared in the malnourished group (adjusted HR 1.08; 95% CI [0.59-2.00]; p=0.798). Mortality rates were significantly lower in the well-nourished group among patients with overweight and obesity.</p><p><strong>Conclusion: </strong>Obesity was associated with reduced 1-year mortality only in AHF patients with good nutritional status, while in malnourished patients, obesity was not associated with 1-year mortality. The prognosis in patients with AHF depends on both the presence of obesity and their nutritional status, highlighting the need for nutritional assessment for risk stratification.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"11 ","pages":"e03"},"PeriodicalIF":4.2,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11904423/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143625898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patient-specific Predictors of Haemolysis with Percutaneous Ventricular Assist Devices. 经皮心室辅助装置对溶血的患者特异性预测。
IF 4.2
Cardiac Failure Review Pub Date : 2025-02-19 eCollection Date: 2025-01-01 DOI: 10.15420/cfr.2024.30
Alexander E Sullivan, Hannah Granger, Leonie Dupuis, Jonathan Napper, Lena Tran, J Lukas Laws, Quinn S Wells, Eric Farber-Eger, Bret D Alvis, Jared M O'Leary, Swaroop Bommareddi, Kaushik V Amancherla, Aniket S Rali
{"title":"Patient-specific Predictors of Haemolysis with Percutaneous Ventricular Assist Devices.","authors":"Alexander E Sullivan, Hannah Granger, Leonie Dupuis, Jonathan Napper, Lena Tran, J Lukas Laws, Quinn S Wells, Eric Farber-Eger, Bret D Alvis, Jared M O'Leary, Swaroop Bommareddi, Kaushik V Amancherla, Aniket S Rali","doi":"10.15420/cfr.2024.30","DOIUrl":"10.15420/cfr.2024.30","url":null,"abstract":"<p><strong>Introduction: </strong>Percutaneous ventricular assist devices (pVADs) are increasingly used in cardiogenic shock but are associated with complications including haemolysis. The aim of this study was to investigate patient characteristics associated with haemolysis in cardiogenic shock patient population.</p><p><strong>Methods: </strong>Consecutive patients were identified using Current Procedural Terminology (CPT) codes for pVAD insertion. Patient characteristics, laboratory and imaging data, and patient outcomes were abstracted manually and using validated automated methods. Laboratory-defined haemolysis required a drop in haemoglobin ≥2 mg/dl with either lactate dehydrogenase ≥250 units/l or undetectable haptoglobin. Clinically significant haemolysis was defined as laboratory-defined haemolysis necessitating transfusion. Primary outcome was the association between haemolysis and on-device and 30-day mortality.</p><p><strong>Results: </strong>A total of 196 patients underwent pVAD insertion for cardiogenic shock during the study period and were included. Laboratory-defined haemolysis occurred in 46 patients (23.5%), of whom 12 (6.1%) had clinically significant haemolysis. Haemolysis occurred more often following emergency insertion, rather than elective insertion (84.8% versus 40.0%, p<0.001) in patients with elevated lactic acid levels (median 2.5 versus 1.6, p=0.016) and elevated heart rates (92.5 BPM versus 86.5 BPM, p=0.023). After multivariable adjustment, there was no association between laboratory-defined haemolysis and on-device (OR 0.6; 95% CI [0.1-3.4]; p=0.565) or 30-day mortality (OR 2.1; 95% CI [0.4-13.0]; p=0.391).</p><p><strong>Conclusion: </strong>Laboratory-defined haemolysis was common in patients with cardiogenic shock and pVAD, but clinically significant haemolysis was not. There was no association between haemolysis and on-device or 30-day mortality.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"11 ","pages":"e04"},"PeriodicalIF":4.2,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11904419/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143626086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Counteracting the Mechanisms of Heart Failure is the Most Effective Way to Decongest Patients while Improving Outcomes. 对抗心力衰竭的机制是缓解患者充血并改善疗效的最有效方法。
IF 4.2
Cardiac Failure Review Pub Date : 2025-02-04 eCollection Date: 2025-01-01 DOI: 10.15420/cfr.2024.19
Jelena Čelutkienė, Alexandre Mebazaa, Jan Biegus, Piotr Ponikowski, Beth Davison, Gad Cotter
{"title":"Counteracting the Mechanisms of Heart Failure is the Most Effective Way to Decongest Patients while Improving Outcomes.","authors":"Jelena Čelutkienė, Alexandre Mebazaa, Jan Biegus, Piotr Ponikowski, Beth Davison, Gad Cotter","doi":"10.15420/cfr.2024.19","DOIUrl":"10.15420/cfr.2024.19","url":null,"abstract":"<p><p>Diuretic therapy is not associated with improved outcomes in heart failure and may cause significant side effects. Counteracting the core pathophysiological mechanisms of heart failure through neurohormonal blockade while reducing reliance on diuretics is potentially the most effective method of decongestion.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"11 ","pages":"e02"},"PeriodicalIF":4.2,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11865671/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143524600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Biomarkers for Congestion in Heart Failure: State-of-the-art and Future Directions. 心力衰竭充血的生物标志物:最新进展和未来方向。
IF 4.2
Cardiac Failure Review Pub Date : 2025-01-27 eCollection Date: 2025-01-01 DOI: 10.15420/cfr.2024.32
Antonio Luca Maria Parlati, Cristina Madaudo, Vincenzo Nuzzi, Paolo Manca, Piero Gentile, Daniela Di Lisi, Antonio Jordán-Ríos, Aamir Shamsi, Mattia Manzoni, Matthew Sadler, Cosmo Godino, Egle Corrado, Stefania Paolillo, Giuseppina Novo, Antonino Tuttolomondo, Alfredo Ruggero Galassi, Pasquale Perrone Filardi, Daniel Bromage, Antonio Cannata
{"title":"Biomarkers for Congestion in Heart Failure: State-of-the-art and Future Directions.","authors":"Antonio Luca Maria Parlati, Cristina Madaudo, Vincenzo Nuzzi, Paolo Manca, Piero Gentile, Daniela Di Lisi, Antonio Jordán-Ríos, Aamir Shamsi, Mattia Manzoni, Matthew Sadler, Cosmo Godino, Egle Corrado, Stefania Paolillo, Giuseppina Novo, Antonino Tuttolomondo, Alfredo Ruggero Galassi, Pasquale Perrone Filardi, Daniel Bromage, Antonio Cannata","doi":"10.15420/cfr.2024.32","DOIUrl":"10.15420/cfr.2024.32","url":null,"abstract":"<p><p>Congestion in patients with heart failure (HF) predicts adverse outcomes and is a leading cause of hospitalisation. Understanding congestion mechanisms helps in HF management and underscores the importance of tailored therapies to treat vascular and tissue congestion, improving patient outcomes. In this setting, several tools are available to detect congestion. Biomarker measurement is a simple, valid and affordable method to evaluate congestion in patients with HF. Natriuretic peptides are the most widely available tool in acute and chronic HF, helping diagnosis, risk stratification and management. Novel biomarkers can potentially become reliable allies in diagnosing and monitoring patients with HF. This review aims to assess the current scientific literature on biomarkers for managing HF, evaluate their clinical utility and explore future perspectives in this field.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"11 ","pages":"e01"},"PeriodicalIF":4.2,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11836606/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143469463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信